KPV

Overview

Tripeptide with powerful anti-inflammatory and immune-regulating properties.

Reported benefits

Reduces inflammation, immune modulation, gut health support

Protocols & dosing

Typical dosage: 500-1000 mcg (daily).

Detailed dosing protocols have not yet been catalogued.

FDA & legal status

KPV is not currently FDA-approved for any indication. Effective April 22, 2026, the FDA removed KPV from Category 2 of its Section 503A bulk drug substances list after the original nominators withdrew their nominations. This removal lifts the prior “significant safety risk” designation but does not place KPV on the 503A Bulks List. Compounding pharmacies may prepare it with a valid physician prescription and pharmaceutical-grade API from an FDA-registered manufacturer. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to review this substance at its July 23–24, 2026 public meeting. Removed from FDA Category 2 effective April 22, 2026. Selected for PCAC review Day 1 — July 23, 2026. PCAC agenda: BPC-157, KPV, TB-500, MOTS-c. NOT currently on 503A Bulks List — requires physician Rx. Source: FDA Advisory Committee Calendar / Lengea Law, May 2026.

Vendor information

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Side effects & safety

Reported side effects: Very well-tolerated

References

No external sources have been catalogued for this article yet.